secwatch.observer — SEC 8-K summary
======================================

Issuer:     Galera Therapeutics, Inc. (GRTX)
CIK:        0001563577
Form:       8-K
Filed at:   2023-10-31T23:59:59+00:00
Accession:  0001193125-23-266704
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Galera: FDA demands new Phase 3 for avasopasem; GRECO-2 futility halts both rucosopasem trials
--------------------------------------------------------------------------------

- FDA reiterated need for an additional Phase 3 trial of avasopasem for radiotherapy-induced SOM.
- GRECO-2 futility analysis (35 deaths, 177 enrolled) led to discontinuation of both GRECO-1 and GRECO-2 trials.
- Preliminary cash, cash equivalents & short-term investments: $28.4M as of Sep 30, 2023.
- Engaged Stifel to review strategic alternatives (merger, sale, licensing); may cease operations if none found.
- Company assessing strategic options to maximize shareholder value; going concern risk noted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563577/000119312523266704/0001193125-23-266704-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563577/000119312523266704/d568178d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-266704

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer